Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

8.490 UNCHANGED
Official Closing Price Updated: 7:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 244,924
Open 8.700
Bid (Size) 8.070 (1)
Ask (Size) 10.52 (1)
Prev. Close 8.490
Today's Range 8.010 - 9.000
52wk Range 5.420 - 23.89
Shares Outstanding 10,262,273
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
From Annovis Bio
Via Business Wire
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-34.64%
-34.64%
1 Month
+36.28%
+36.28%
3 Month
-31.20%
-31.20%
6 Month
-35.92%
-35.92%
1 Year
-35.14%
-35.14%

More News

Read More
Recap: Annovis Bio Q1 Earnings
Via Benzinga
Why Annovis Bio (ANVS) Stock Hit A New 52-Week Low Today
Via Benzinga
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Annovis Bio Announces Pricing of $7.5 Million Public Offering
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Announces Launch of Proposed Public Offering
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update
From Annovis Bio, Inc.
Via Business Wire
3 Biotech Stocks to Buy Before Drug Trials End
Via InvestorPlace
Continued Positive Performance of Novel Drug Development by Annovis Bio Presented at 2023 Alzheimer's Association International Conference
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Announces the Filing of a Groundbreaking Patent
From Annovis Bio, Inc.
Via Business Wire
Annovis Bio Receives Excellent Safety Rating and Positive Recommendation to Continue Phase III Trial of Buntanetap for Parkinson’s Disease Patients from the Independent Data and Safety Monitoring Board (DSMB)
From Annovis Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Tesla, NIO And Other Big Stocks Moving Lower On Monday
Via Benzinga
Why Heska Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead
Via Talk Markets
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Ensysce Biosciences, AST SpaceMobile, IGM Biosciences And Other Big Stocks Moving Lower On Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Dear PSNY Stock Fans, Mark Your Calendars for Oct. 12
Via InvestorPlace
Why Is Annovis Bio (ANVS) Stock Up 12% Today?
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.